Developer docs
API playgroundTry for free, no card

Search company profiles

Readily3D

Full company profile

uuid00041uq

Namestring
Readily3D
Legal namestring
Readily3D SA
Websiteurl
readily3d.com
Company typeenum
Private
Founded yearint
2020
Descriptiontext

Readily3D SA is a privately held Swiss developer of volumetric 3D bioprinters headquartered at the EPFL Innovation Park in Lausanne. The company commercializes a tomographic volumetric bioprinting technology originally invented by co-founders Paul Delrot and Prof. Christophe Moser during research at EPFL; in this approach, shaped light beams from multiple angles simultaneously solidify photosensitive, cell-laden inks throughout a build volume, producing centimeter-scale biological constructs (including organoids and vascular-network-bearing tissues) in seconds rather than the minutes-to-hours of conventional layer-by-layer extrusion bioprinters. Readily3D's technology is contactless and reportedly preserves high cell viability (>95% at 10 days for human hepatic organoids, >90% at 7 days for C2C12 myoblasts and normal human dermal fibroblasts) at optical resolution below 100 µm with low photoinitiator content (1 mg/mL LAP) and light dose (<600 mJ/cm²).

The commercial product line consists of the Tomolite v2.0 modular volumetric bioprinter (offered in Standard, E, Performance and Polychromatic configurations), the Apparite software platform (STL import, light-dose computation, object registration, live monitoring, cloud-accelerated beam computation in roughly 30-90 seconds), and a Multi-wavelength Add-on supporting up to four laser lines from 400 nm to 750 nm developed under the EU Horizon 2020 ENLIGHT project. The company is monetized through direct, quote-based hardware sales (Tomolite systems and add-on modules) supported by Apparite software and technical support services, with no disclosed resale or distribution channel. Go-to-market relies on direct enterprise sales, the appointment of Randy Heyler as North America business developer, scientific-conference presence (European Organ-on-chip Society, European Society for Biomaterials, Summer School on Light-Based 3D Printing) and a publication-driven credibility strategy anchored by more than 50 peer-reviewed papers.

The core customer segments are life-science researchers in academia, pharmaceutical and biotech companies, and academic medical centers such as Utrecht University and University Medical Center Utrecht, where the platform is used for biofabrication, organoid biology, disease modeling, tissue regeneration and drug discovery. The company is funded primarily through non-dilutive sources — a Venture Kick award, MassChallenge participation and two ongoing Eurostars/Eureka grants (VOLTA-E, December 2023 - September 2026; PREPPER-E, December 2024 - December 2026) — with no disclosed equity financing. Intellectual property is anchored by 16 granted patents spanning the US, Europe, Japan, China, Korea, Singapore and Australia.

Short descriptiontext

Readily3D SA is a Lausanne-based Swiss spin-out of EPFL that develops and sells the Tomolite, a tomographic volumetric 3D bioprinter that solidifies cell-laden inks with shaped light from multiple angles to build centimeter-scale living tissue constructs in seconds for life-science research, pharmaceutical and academic medical-center customers.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersLausanne, Switzerland
HQ citystring
Lausanne
HQ countrystring
Switzerland
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
volumetric 3D bioprinting, bioprinting equipment, tissue engineering hardware, bioprinter software, biofabrication systems
Industry4 codes
PRIMARYIMAAAAAG
Bioprinting & Biofabrication Systems (Tissue/Cell Printing Hardware)
Industrials, Manufacturing & Construction/3D Printing/3D Printing Hardware (Printers & Systems)
SECONDARYHDACAEAH
3D Printers (Additive Manufacturing)
Hardware, Technology & Telecom/Computing Hardware & Peripherals/Printers, Scanners & Imaging Peripherals
SECONDARYIMAAAFAI
Medical & Dental Prototyping (Models, Guides, Pre-Op Planning)
Industrials, Manufacturing & Construction/3D Printing/Rapid Prototyping & Product Development (Additive)
SECONDARYIMAAAAAL
3D Printer Automation & Peripheral Hardware (Material Handling, Depowdering, Build Units)
Industrials, Manufacturing & Construction/3D Printing/3D Printing Hardware (Printers & Systems)
NAICS code1 code
  • Medical Equipment and Supplies Manufacturing3391
SIC code1 code
  • Surgical & Medical Instruments & Apparatus3841
Product category
3D Bioprinters
Social media profiles1 record
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model4 records
1Tomolite Bioprinter Sales
TypeHardware Sales
Description

Sale of Tomolite v2.0 modular tomographic volumetric bioprinter with different versions (Standard, E, Performance, Polychromatic). One-time hardware purchase with potential add-on modules.

readily3d.com
2Apparite Software License
TypeSubscription Recurring
Description

Software platform for bioprinter operation. Supported on Windows 7 and 10. Likely sold as license with potential for updates and support contracts.

readily3d.com
3Multi-wavelength Add-on Module
TypeHardware Sales
Description

Modular add-on for Tomolite v2 enabling multi-wavelength printing. Can be purchased as upgrade to existing systems or bundled with new purchases.

readily3d.com
4Technical Support and Services
TypeProfessional Services
Description

Technical support services including online appointments for technical inquiries. Professional services for setup and training likely available.

readily3d.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Supply Chain, Marketing or Sales
Pricing details1 tier
1Custom quotation-based pricing
ModelOtherBilling cadencePay-as-you-go
Notes

No public pricing available. Contact sales at contact@readily3d.com for quote requests. Product bundle options include base Tomolite v2.0, multi-wavelength add-on module, and Apparite software.

readily3d.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 3 records shown
1Tomolite
Description

Volumetric bioprinter product line including Tomolite v2.0 with versions: Standard, E, Performance and Polychromatic.

readily3d.com
+2 more records
Core offering1 text field

Readily3D manufactures and sells the Tomolite, a tomographic volumetric 3D bioprinter that fabricates centimeter-scale living tissue and organoid constructs in a single light-projection step (typically 10–30 seconds). The hardware is operated through its companion Apparite software and can be extended with a multi-wavelength add-on for multi-material and multi-cell printing.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • Human hepatic organoids: >95% viability after 10 days, printed in 15.5 seconds
+5 more records
Product overview1 text field

Readily3D offers a modular volumetric 3D bioprinting system consisting of the Tomolite bioprinter as the core hardware platform, supported by the Apparite software for workflow control. The Tomolite v2.0 supports modular upgrades including the Multi-wavelength Add-on for polychromatic printing applications. The company also develops add-on modules and software enhancements to extend the platform's capabilities for life science research.

Product and service3 records
1Tomolite v2.0 Bioprinter
CategoryVolumetric 3D Bioprinting Hardware
2Apparite Software
CategoryBioprinter Control Software
3Multi-wavelength Add-on
CategoryBioprinter Hardware Add-on
Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-12-01
Description

Ongoing Eurostars VOLTA-E!3908 project (December 2023 - September 2026) and Eurostars PREPPER-E!6780 (December 2024 - December 2026) supported by Eureka Network. These R&D projects advance volumetric bioprinting applications and technology development.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Core technology originated from EPFL research. Prof. Christophe Moser, full professor at EPFL, is co-founder and board member. Company is based at EPFL Innovation Park. Ongoing technology transfer and research collaboration.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Prof. Riccardo Levato, associate professor at Utrecht University and UMC Utrecht, serves as scientific advisor. He pioneered volumetric bioprinting for tissue printing and contributes expertise in bioprinting applications.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Multi-wavelength add-on developed as outcome of ENLIGHT project, funded by European Union's Horizon 2020 research and innovation program under grant agreement No. 964497.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

French bioprinting company using laser-assisted bioprinting for tissue engineering and pharmaceutical applications. Comparable as a European bioprinting technology company targeting pharma R&D and regenerative medicine use cases.

TypeDirect peer
Description

Swiss bioprinter manufacturer offering modular multi-head bioprinters for tissue engineering and regenerative medicine research. Comparable as a Europe-based bioprinting hardware vendor with modular product design serving academic and pharma research.

TypeBroad incumbent
Description

Large incumbent in 3D printing with extensive medical/life science offerings including the Allevi bioprinting line and regenerative medicine programs. Comparable as a broad medical 3D printing player, though bioprinting is a small part of its portfolio.

4Aspect Biosystems
TypeDirect peer
Description

Developer of microfluidic 3D bioprinting technology for tissue therapeutics and preclinical drug testing. Comparable as a bioprinting platform targeting pharma/biotech partnerships in tissue engineering and drug discovery.

TypeEmerging player
Description

Finnish modular 3D bioprinter company targeting tissue engineering and pharma research with multi-material printing capabilities. Comparable as an emerging European modular bioprinter vendor focused on academic and translational research customers.

TypeDirect peer
Description

Pioneer in 3D bioprinted human tissue for drug discovery and disease modeling. Comparable as a bioprinting-focused life science tools company pursuing pharma and academic customers with tissue construct outputs.

TypeDirect peer
Description

German manufacturer of specialized 3D bioprinters and bio-printing platforms for research applications. Comparable as a small European bioprinter vendor serving academic tissue engineering and regenerative medicine labs.

TypeDirect peer
Description

Largest dedicated bioprinting company globally, offering extrusion-based BIO X and other 3D bioprinters, bioinks, and lab automation. Directly comparable as a bioprinter vendor serving tissue engineering and pharma research customers, though operating at vastly larger scale with a broader bioink/consumables revenue model.

TypeBroad incumbent
Description

Major 3D printing incumbent with PolyJet and FDM technologies serving healthcare and life sciences. Comparable as a broader 3D printing hardware company with medical/healthcare adjacencies, though not a bioprinting specialist.

10Allevi (a 3D Systems company)
TypeDirect peer
Description

Bioprinter and bioink vendor acquired by 3D Systems, offering extrusion-based 3D bioprinters for life science research. Comparable as a bioprinting platform targeting academic tissue engineering and drug discovery labs.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Readily3D

3D Bioprintersreadily3d.com

Readily3D SA is a Lausanne-based Swiss spin-out of EPFL that develops and sells the Tomolite, a tomographic volumetric 3D bioprinter that solidifies cell-laden inks with shaped light from multiple angles to build centimeter-scale living tissue constructs in seconds for life-science research, pharmaceutical and academic medical-center customers.

What Readily3D does

Readily3D SA is a privately held Swiss developer of volumetric 3D bioprinters headquartered at the EPFL Innovation Park in Lausanne. The company commercializes a tomographic volumetric bioprinting technology originally invented by co-founders Paul Delrot and Prof. Christophe Moser during research at EPFL; in this approach, shaped light beams from multiple angles simultaneously solidify photosensitive, cell-laden inks throughout a build volume, producing centimeter-scale biological constructs (including organoids and vascular-network-bearing tissues) in seconds rather than the minutes-to-hours of conventional layer-by-layer extrusion bioprinters. Readily3D's technology is contactless and reportedly preserves high cell viability (>95% at 10 days for human hepatic organoids, >90% at 7 days for C2C12 myoblasts and normal human dermal fibroblasts) at optical resolution below 100 µm with low photoinitiator content (1 mg/mL LAP) and light dose (<600 mJ/cm²).

The commercial product line consists of the Tomolite v2.0 modular volumetric bioprinter (offered in Standard, E, Performance and Polychromatic configurations), the Apparite software platform (STL import, light-dose computation, object registration, live monitoring, cloud-accelerated beam computation in roughly 30-90 seconds), and a Multi-wavelength Add-on supporting up to four laser lines from 400 nm to 750 nm developed under the EU Horizon 2020 ENLIGHT project. The company is monetized through direct, quote-based hardware sales (Tomolite systems and add-on modules) supported by Apparite software and technical support services, with no disclosed resale or distribution channel. Go-to-market relies on direct enterprise sales, the appointment of Randy Heyler as North America business developer, scientific-conference presence (European Organ-on-chip Society, European Society for Biomaterials, Summer School on Light-Based 3D Printing) and a publication-driven credibility strategy anchored by more than 50 peer-reviewed papers.

The core customer segments are life-science researchers in academia, pharmaceutical and biotech companies, and academic medical centers such as Utrecht University and University Medical Center Utrecht, where the platform is used for biofabrication, organoid biology, disease modeling, tissue regeneration and drug discovery. The company is funded primarily through non-dilutive sources — a Venture Kick award, MassChallenge participation and two ongoing Eurostars/Eureka grants (VOLTA-E, December 2023 - September 2026; PREPPER-E, December 2024 - December 2026) — with no disclosed equity financing. Intellectual property is anchored by 16 granted patents spanning the US, Europe, Japan, China, Korea, Singapore and Australia.

Readily3D firmographics

Firmographics
Name
Readily3D
Legal name
Readily3D SA
Website
https://readily3d.com
Company type
Private
Founded year
2020
Operating status
Operating
Headcount range
11–50 employees
Short description
Readily3D SA is a Lausanne-based Swiss spin-out of EPFL that develops and sells the Tomolite, a tomographic volumetric 3D bioprinter that solidifies cell-laden inks with shaped light from multiple angles to build centimeter-scale living tissue constructs in seconds for life-science research, pharmaceutical and academic medical-center customers.
Ownership category
akta.pro rank

Readily3D industry classification

Industry
Product category
3D Bioprinters
NAICS
Medical Equipment and Supplies Manufacturing (3391)
SIC
Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYIMAAAAAG
Bioprinting & Biofabrication Systems (Tissue/Cell Printing Hardware)
Industrials, Manufacturing & Construction/3D Printing/3D Printing Hardware (Printers & Systems)
SECONDARYHDACAEAH
3D Printers (Additive Manufacturing)
Hardware, Technology & Telecom/Computing Hardware & Peripherals/Printers, Scanners & Imaging Peripherals
SECONDARYIMAAAFAI
Medical & Dental Prototyping (Models, Guides, Pre-Op Planning)
Industrials, Manufacturing & Construction/3D Printing/Rapid Prototyping & Product Development (Additive)
SECONDARYIMAAAAAL
3D Printer Automation & Peripheral Hardware (Material Handling, Depowdering, Build Units)
Industrials, Manufacturing & Construction/3D Printing/3D Printing Hardware (Printers & Systems)

Keywords

  • Volumetric 3D bioprinting
  • Bioprinting equipment
  • Tissue engineering hardware
  • Bioprinter software
  • Biofabrication systems

Where Readily3D is headquartered

Location

Headquarters

HQ city
Lausanne
HQ country
Switzerland
HQ region
Europe

Offices2 records

Markets served

Readily3D business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Supply Chain, Marketing or Sales

Revenue model

  1. Tomolite Bioprinter Sales: Sale of Tomolite v2.0 modular tomographic volumetric bioprinter with different versions (Standard, E, Performance, Polychromatic). One-time hardware purchase with potential add-on modules.
  2. Apparite Software License: Software platform for bioprinter operation. Supported on Windows 7 and 10. Likely sold as license with potential for updates and support contracts.
  3. Multi-wavelength Add-on Module: Modular add-on for Tomolite v2 enabling multi-wavelength printing. Can be purchased as upgrade to existing systems or bundled with new purchases.
  4. Technical Support and Services: Technical support services including online appointments for technical inquiries. Professional services for setup and training likely available.

Pricing tiers

ModelBillingPrice
OtherPay-as-you-goCustom quotation-based pricing

Go-to-market motion3 records

Distribution channels3 records

Marketing channels6 records

Readily3D product offering

Product offering

Core offering

Readily3D manufactures and sells the Tomolite, a tomographic volumetric 3D bioprinter that fabricates centimeter-scale living tissue and organoid constructs in a single light-projection step (typically 10–30 seconds). The hardware is operated through its companion Apparite software and can be extended with a multi-wavelength add-on for multi-material and multi-cell printing.

Product overview

Readily3D offers a modular volumetric 3D bioprinting system consisting of the Tomolite bioprinter as the core hardware platform, supported by the Apparite software for workflow control. The Tomolite v2.0 supports modular upgrades including the Multi-wavelength Add-on for polychromatic printing applications. The company also develops add-on modules and software enhancements to extend the platform's capabilities for life science research.

Differentiator

Problem solved

Functional benefit

Brands

  • Tomolite: Volumetric bioprinter product line including Tomolite v2.0 with versions: Standard, E, Performance and Polychromatic.
  • Apparite
  • Tomolite Add-on

Products and services

  • Tomolite v2.0 Bioprinter
  • Apparite Software
  • Multi-wavelength Add-on

Quantifiable outcome

  • Human hepatic organoids: >95% viability after 10 days, printed in 15.5 seconds
  • +5 more outcomes

Companies that use Readily3D

Customer profile

Segments3 records

Ideal customer profiles3 records

Readily3D technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature6 records

Readily3D partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered core and minor.

  • Eurostars (Eureka Network)coreStrategic or Co-development Partner · 1 December 2023Ongoing Eurostars VOLTA-E!3908 project (December 2023 - September 2026) and Eurostars PREPPER-E!6780 (December 2024 - December 2026) supported by Eureka Network. These R&D projects advance volumetric bioprinting applications and technology development.
  • EPFL (École Polytechnique Fédérale de Lausanne)coreStrategic or Co-development PartnerCore technology originated from EPFL research. Prof. Christophe Moser, full professor at EPFL, is co-founder and board member. Company is based at EPFL Innovation Park. Ongoing technology transfer and research collaboration.
  • Utrecht University / University Medical Center UtrechtminorStrategic or Co-development PartnerProf. Riccardo Levato, associate professor at Utrecht University and UMC Utrecht, serves as scientific advisor. He pioneered volumetric bioprinting for tissue printing and contributes expertise in bioprinting applications.
  • European Union Horizon 2020 (ENLIGHT Project)coreStrategic or Co-development PartnerMulti-wavelength add-on developed as outcome of ENLIGHT project, funded by European Union's Horizon 2020 research and innovation program under grant agreement No. 964497.

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

Readily3D competitors and assessment

Company assessment

Direct peers

  • Poietis: French bioprinting company using laser-assisted bioprinting for tissue engineering and pharmaceutical applications. Comparable as a European bioprinting technology company targeting pharma R&D and regenerative medicine use cases.
  • RegenHU: Swiss bioprinter manufacturer offering modular multi-head bioprinters for tissue engineering and regenerative medicine research. Comparable as a Europe-based bioprinting hardware vendor with modular product design serving academic and pharma research.
  • Aspect Biosystems: Developer of microfluidic 3D bioprinting technology for tissue therapeutics and preclinical drug testing. Comparable as a bioprinting platform targeting pharma/biotech partnerships in tissue engineering and drug discovery.
  • Organovo: Pioneer in 3D bioprinted human tissue for drug discovery and disease modeling. Comparable as a bioprinting-focused life science tools company pursuing pharma and academic customers with tissue construct outputs.
  • GeSiM: German manufacturer of specialized 3D bioprinters and bio-printing platforms for research applications. Comparable as a small European bioprinter vendor serving academic tissue engineering and regenerative medicine labs.
  • BICO (formerly CELLINK): Largest dedicated bioprinting company globally, offering extrusion-based BIO X and other 3D bioprinters, bioinks, and lab automation. Directly comparable as a bioprinter vendor serving tissue engineering and pharma research customers, though operating at vastly larger scale with a broader bioink/consumables revenue model.
  • Allevi (a 3D Systems company): Bioprinter and bioink vendor acquired by 3D Systems, offering extrusion-based 3D bioprinters for life science research. Comparable as a bioprinting platform targeting academic tissue engineering and drug discovery labs.

Broad incumbents

  • 3D Systems: Large incumbent in 3D printing with extensive medical/life science offerings including the Allevi bioprinting line and regenerative medicine programs. Comparable as a broad medical 3D printing player, though bioprinting is a small part of its portfolio.
  • Stratasys: Major 3D printing incumbent with PolyJet and FDM technologies serving healthcare and life sciences. Comparable as a broader 3D printing hardware company with medical/healthcare adjacencies, though not a bioprinting specialist.

Emerging players

  • Brinter: Finnish modular 3D bioprinter company targeting tissue engineering and pharma research with multi-material printing capabilities. Comparable as an emerging European modular bioprinter vendor focused on academic and translational research customers.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Readily3D social profiles

Digital presence

Readily3D financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Readily3D leadership team

Management profile

Number of profiles

Profiles5 records

Readily3D funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Readily3D M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Readily3D

What does Readily3D do?

Readily3D manufactures and sells the Tomolite, a tomographic volumetric 3D bioprinter that fabricates centimeter-scale living tissue and organoid constructs in a single light-projection step (typically 10–30 seconds). The hardware is operated through its companion Apparite software and can be extended with a multi-wavelength add-on for multi-material and multi-cell printing.

Is Readily3D a public or private company?

Readily3D is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Readily3D founded?

Readily3D was founded in 2020. It employs 11 to 50 people.

Where is Readily3D based?

Readily3D is headquartered in Lausanne, Switzerland, in the Europe region.

How does Readily3D make money?

Four revenue lines are on record. Tomolite Bioprinter Sales are the primary driver. The others are apparite Software License, multi-wavelength Add-on Module and technical Support and Services.

Who are Readily3D's main competitors?

Direct peers on record are Poietis, RegenHU, Aspect Biosystems, Organovo, GeSiM, BICO (formerly CELLINK) and Allevi (a 3D Systems company). Broad incumbents are 3D Systems and Stratasys. Brinter is listed as an emerging player.

Does Readily3D have an API?

No public API is recorded for Readily3D.

What industry is Readily3D in?

Readily3D's product category is 3D Bioprinters. Its primary akta.pro industry code is IMAAAAAG, Bioprinting & Biofabrication Systems (Tissue/Cell Printing Hardware), with a secondary code of HDACAEAH, 3D Printers (Additive Manufacturing). Its NAICS code is 3391 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
startupticker.chExecutive changes to fuel further growthReadily3D, Visium, BLP, and Scait appointed new C-suite executives to support growth. Readily3D's CEO Diego Dupouy and CTO Paul Delrot joined, Visium added Tomislav Ilicic and Andrea Tassistro, BLP hired Marc Zinnemers as CFO, and Scait appointed Christoph Santschi as sales chief.Startup WeeklySwedish biotech VERIGRAFT secures €1.2m to advance personalized 3D-printed arterial graftsSwedish biotech VERIGRAFT secured a €1.2 million Eurostars grant to lead PREPPER, a project developing 3D-printed arterial grafts with partners including Readily3D, RISE, and Sahlgrenska University Hospital. The project aims to create customized vascular grafts that mimic natural arteries, with a first-in-human clinical trial planned.MedicalxpressBioprinted mini pancreas will help in the fight against diabetesEPFL's Readily3D developed a bioprinting system that creates a mini pancreas from human stem cells in 30 seconds. The technology is being used in the EU-funded Enlight project to develop a living model for testing diabetes medications. The firm also sees potential for bioprinting other tissues, including for cancer treatments and transplant organs.UbergizmoResearchers Develop A New Highly-Precise, Extremely Fast 3D Printing ProcessEPFL researchers developed a new 3D printing process that prints highly precise objects in seconds. The process, tested on 3D printed arteries with a surgeon, is limited to 2cm structures but aims to reach 15cm. The technology could be applied in medical fields.